Roivant Sciences Ltd.ROIVNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -42.05% | -16.08% | -72.84% | -64.89% | -77.83% |
| Gross Profit Growth | -42.99% | +8.71% | -74.08% | -65.57% | -85.17% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -105.35% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -96.68% | +0.00% | -334.38% | +0.00% | -256.98% |
| EPS Growth | -96.39% | +0.00% | -353.85% | +0.00% | -265.22% |
| EPS Diluted Growth | -96.19% | +0.00% | -375.00% | +0.00% | -265.22% |
| Weighted Average Shares Growth | -9.73% | -11.90% | -7.55% | -7.41% | -3.58% |
| Weighted Average Shares Diluted Growth | -14.42% | -11.90% | -12.97% | -7.41% | -3.58% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +127.54% | -100.00% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | -100.00% | -100.00% | -100.00% | +0.00% | +0.00% |
| Asset Growth | -20.79% | -24.72% | -22.53% | -18.42% | -9.79% |
| Book Value per Share Growth | -5.60% | -10.85% | -13.52% | -8.56% | -14.68% |
| Debt Growth | -80.20% | -79.96% | -73.70% | +87.53% | +106.79% |
| R&D Expense Growth | +30.93% | +36.14% | +26.90% | +15.61% | +16.80% |
| SG&A Expenses Growth | +10.43% | +37.56% | +34.16% | -29.07% | +23.69% |